Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives $20.05 Average PT from Analysts

Alignment Healthcare, Inc. (NASDAQ:ALHC) has received a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $20.35.

A number of brokerages have commented on ALHC. UBS Group upped their price objective on Alignment Healthcare from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Barclays boosted their target price on shares of Alignment Healthcare from $13.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, October 31st. KeyCorp reaffirmed an “overweight” rating on shares of Alignment Healthcare in a research report on Monday, November 24th. The Goldman Sachs Group reiterated a “buy” rating and issued a $22.00 price objective on shares of Alignment Healthcare in a research note on Monday, November 3rd. Finally, Zacks Research lowered shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th.

Alignment Healthcare Stock Up 0.0%

Alignment Healthcare stock opened at $20.42 on Monday. The company’s 50-day moving average price is $17.95 and its two-hundred day moving average price is $16.00. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99. The stock has a market cap of $4.09 billion, a P/E ratio of -170.17 and a beta of 1.16. Alignment Healthcare has a twelve month low of $10.18 and a twelve month high of $21.06.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The company had revenue of $993.70 million during the quarter, compared to analysts’ expectations of $980.90 million. Alignment Healthcare had a negative return on equity of 16.23% and a negative net margin of 0.57%.The business’s revenue was up 43.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.14) earnings per share. As a group, analysts expect that Alignment Healthcare will post -0.69 EPS for the current year.

Insider Buying and Selling at Alignment Healthcare

In other news, CEO John E. Kao sold 180,000 shares of the company’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $19.02, for a total transaction of $3,423,600.00. Following the completion of the sale, the chief executive officer directly owned 2,346,726 shares in the company, valued at approximately $44,634,728.52. This represents a 7.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, President Dawn Christine Maroney sold 113,319 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $20.01, for a total value of $2,267,513.19. Following the sale, the president directly owned 1,667,237 shares in the company, valued at approximately $33,361,412.37. This trade represents a 6.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 842,157 shares of company stock valued at $15,187,475 over the last ninety days. 7.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alignment Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its stake in Alignment Healthcare by 167.3% during the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after buying an additional 6,940,277 shares in the last quarter. Invesco Ltd. boosted its position in shares of Alignment Healthcare by 122.3% during the 2nd quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after acquiring an additional 2,294,739 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Alignment Healthcare by 13.2% during the 1st quarter. Vanguard Group Inc. now owns 11,113,896 shares of the company’s stock worth $206,941,000 after acquiring an additional 1,295,825 shares in the last quarter. Marshall Wace LLP increased its stake in Alignment Healthcare by 173.3% in the second quarter. Marshall Wace LLP now owns 2,039,714 shares of the company’s stock valued at $28,556,000 after acquiring an additional 1,293,416 shares during the last quarter. Finally, Voya Investment Management LLC raised its position in Alignment Healthcare by 61.0% during the third quarter. Voya Investment Management LLC now owns 3,196,297 shares of the company’s stock valued at $55,775,000 after purchasing an additional 1,210,930 shares in the last quarter. Institutional investors own 86.19% of the company’s stock.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.